Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and lethal disorder of the blood in which the body attacks and destroys red blood cells in massive amounts. This focus collection and short ...
Following achievements in Asia, Roche's PNH treatment drug PIASKY (crovalimab) received its first FDA approval. This approval has spiked the competition between Roche and current market leader ...
PAROXYSMAL nocturnal hemoglobinuria is a rarely recognized cause of hemolytic anemia. Although the exact etiology remains obscure, the erythrocytes develop a defect that sensitizes them to increased ...
"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...
The expected launch of potential therapies such as Pozelimab + Cemdisiran (Regeneron Pharmaceuticals), Zaltenibart (OMS906; Novo Nordisk), Ruxoprubart (NM8074; NovelMed Therapeutics), NM5072 (NovelMed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results